Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces its participation in ...
Belgian biotechnology firm Cardio3 BioSciences has secured approval from the Italian Medicines Agency (Agenzia Italiana del Farmaco) to start its congestive heart failure cardiopoietic regenerative therapy (CHART-1) European Phase III trial ...
Tags: Cardio3 Biosciences, C-Cure Drug